Abstracts Found in Various Medical Journals Concerning Peritoneal Mesothelioma

Abstracts Found in Various Medical Journals Concerning Peritoneal
Mesothelioma Peritoneal mesothelioma in a 17-year-old boy with evidence
of previous exposure to chrysotile and tremolite asbestos.
Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma:
favorable outcome with a multimodality approach. Intestinal obstruction
due to diffuse peritoneal fibrosis at 2 years after the successful
treatment of malignant peritoneal mesothelioma with intraperitoneal
mitoxantrone. Malignant peritoneal mesothelioma in childhood with
long-term survival. Successful therapy of peritoneal mesothelioma with
intraperitoneal chemotherapy alone. A case report. Intraperitoneal
chemotherapy for malignant peritoneal mesothelioma. Efficacy of
cisplatin-based intraperitoneal chemotherapy as treatment of malignant
peritoneal mesothelioma. Death certificate categorization of malignant
pleural and peritoneal mesothelioma in a cohort of asbestos insulation
workers. Asbestos, laryngeal carcinoma, and malignant peritoneal
mesothelioma in an insulation worker. Year: 1994 Peritoneal
mesothelioma in a 17-year-old boy with evidence of previous exposure to
chrysotile and tremolite asbestos. Abstract: We describe a case of
malignant peritoneal mesothelioma arising in a 17-year-old boy. The
diagnosis was based on a comprehensive study including light
microscopy, histochemistry, immunohistochemistry, evaluation of the
clinical course, and autopsy examination. Analytical transmission
electron microscopy showed a concentration of 510,000 asbestos fibers/g
dry lung tissue. The fibers were represented by chrysotile (62%) and
tremolite (38%) asbestos. About 40% of the total fibers were longer
than 5 microns. The presence of tremolite fibers was probably due to
environmental exposure to contaminated cosmetic talc. This is the first
reported case of pathologically proven exposure to asbestos dust in
malignant mesothelioma of childhood and adolescence. Hum Pathol1994
Jun, vol. 25, pages 617-622 UNITED STATESAndrion A and Bosia SDivision
of Pathological Anatomy, City Hospital, Asti, Italy. * * * * * * * * *
* Year: 1993 Intraperitoneal cisplatin and etoposide in peritoneal
mesothelioma: favorable outcome with a multimodality approach.
Abstract: Ten patients with histologically documented peritoneal
mesothelioma were treated with intraperitoneal cisplatin 200 mg/m2,
sodium thiosulfate rescue and etoposide 65-290 mg/m2 every 4 weeks for
a maximum of six cycles. All had epithelial or mixed epithelial-fibrous
histology. Toxicity was tolerable, with 50% sustaining grade 3 or 4
granulocytopenia. There was one episode of neutropenic fever. Grade 2
peripheral neuropathy occurred in one patient, grade 1 in five
patients. Complete remission occurred in one of five patients with
measurable disease. Median survival for patients whose tumors were
surgically debulked to < 2 cm residua prior to treatment was 22
months, while it was 5 months for those with measurable, surgically
inaccessible disease (P = 0.0731 by Cox regression proportional hazard
model). These data suggest that patients who present with resectable
disease may benefit from an aggressive adjuvant approach. This
possibility warrants prospective testing in a randomized clinical
trial. Cancer Chemother Pharmacol1993, vol. 32, pages 204-208 GERMANY
Langer CJ and Rosenblum NDepartment of Medical Oncology, Fox Chase
Cancer Center, Philadelphia, PA 19111. * * * * * * * * * * Year: 1992
Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years
after the successful treatment of malignant peritoneal mesothelioma
with intraperitoneal mitoxantrone [published erratum appears in Cancer
Chemother Pharmacol 1992;30(3):249] Abstract: A 44-year-old man who had
achieved a complete remission of malignant peritoneal mesothelioma
after the intraperitoneal administration of 25 mg/m2 mitoxantrone
presented with clinical and radiological signs of intestinal
obstruction suggestive of recurrent disease at about 2 years following
the initial treatment. However, laparotomy revealed extensive adhesive
fibrosis but no sign of malignant mesothelioma. The peritoneal
complications of intraperitoneal cytostatic treatment are discussed.
Cancer Chemother Pharmacol1992, vol. 29, pages 405-408 GERMANY Vlasveld
LT and Taal BGDepartment of Medical Oncology, The Netherlands Cancer
Institute, Antoni van Leeuwenhoek Huis, Amsterdam. * * * * * * * * * *
Year: 1991 Malignant peritoneal mesothelioma in childhood with
long-term survival. Abstract: A diffuse, well-differentiated, malignant
peritoneal mesothelioma (MPM) developed in a nine-year-old girl. She
received limited chemotherapy and radiation therapy and is alive and
well without clinical evidence of disease 109 months after diagnosis.
The neoplastic cells stained immunohistochemically for cytokeratin and
epithelial membrane antigen but were unreactive with B72.3,
anti-carcinoembryonic antigen, and anti-Leu-M1. Ultrastructurally, the
tumor cells had abundant desmosomes, numerous tonofilament bundles, and
variable-length microvilli. These findings confirm the mesothelial
nature of the cells. Features consistent with malignancy included DNA
aneuploidy by flow cytometric analysis and diffuse peritoneal
involvement. The three previously described survivors with MPM were
also premenarchal girls. Some MPMs in premenarchal girls have an
indolent biologic behavior similar to that of low-grade peritoneal
serous neoplasia or well-differentiated papillary mesothelioma in adult
women. Am J Clin Pathol1991 Apr, vol. 95, pages 493-498Geary WA, Mills
SE and Frierson HF, JrDepartment of Pathology, University of Virginia
Health Sciences Center, Charlottesville 22908. * * * * * * * * * *
Year: 1992 Successful therapy of peritoneal mesothelioma with
intraperitoneal chemotherapy alone. A case report. Abstract: Malignant
peritoneal mesothelioma is a disease that remains relatively refractory
to conventional intravenous chemotherapy with currently available
agents. Single-agent and combination chemotherapy offer a response rate
of 20%. Direct intraperitoneal administration of some chemotherapeutic
agents results in a significant pharmacologic advantage with much
greater area under the concentration versus time curve (AUC). We report
a case of a patient with peritoneal mesothelioma treated with
combination intraperitoneal cisplatin and Ara-C who achieved a
pathologic complete remission. This patient is still alive and has been
in complete remission for 53 months. This combination of
intraperitoneal chemotherapy deserves further evaluation in malignant
mesothelioma. Am J Clin Oncol1992 Dec, vol 15, pages 528-530 UNITED
STATES Garcia Moore MLSection of Medical Oncology, University of Miami
School of Medicine, Florida 33121. * * * * * * * * * * Year: 1991
Intraperitoneal chemotherapy for malignant peritoneal mesothelioma
[published erratum appears in Eur J Cancer 1991;27(12):1717] Abstract:
4 patients with malignant peritoneal mesothelioma have been treated
with intraperitoneal chemotherapy in the Netherlands Cancer Institute
in the recent years. 1 patient achieved a complete remission for 36+
months and another patient had a partial remission that lasted for 10
months. Intraperitoneal chemotherapy alone or in combination with other
treatment modalities may yield a response rate of 58% with 24% complete
remissions in 70 patients reviewed in the literature. Although these
data should be considered with caution because of the heterogenicity of
the patient group treated, cisplatin-based intraperitoneal chemotherapy
seems to be the best available treatment for malignant peritoneal
mesothelioma at present. Eur J Cancer1991, vol. 27, pages 732-734
ENGLAND Vlasveld LTDepartment of Medical Oncology, Netherlands Cancer
Institute, Amsterdam. * * * * * * * * * * Year: 1992 Efficacy of
cisplatin-based intraperitoneal chemotherapy as treatment of malignant
peritoneal mesothelioma. Abstract: In an effort to examine the
potential clinical utility of intraperitoneal (i.p.) therapy in the
management of patients with malignant peritoneal mesothelioma, 19
individuals with this disease were treated with a cisplatin-based i.p.
treatment regimen. All but 1 patient also received i.p. mitomycin. The
treatment was generally well tolerated, although a maximum of only four
or five courses of cisplatin (100 mg/m2 every 28 days) and mitomycin
(5-10 mg/treatment given 7 days after each i.p. cisplatin
administration) could be administered, the treatment principally being
stopped because of disease progression or catheter failure. Of 15
patients with malignant ascites, 7 (47%) experienced control of fluid
reaccumulation ranging from 2 months to 73+ months (median 8 months).
While the median survival for the 19 patients was only 9 months, 4
(21%) patients survived for more than 3 years from the initiation of
therapy, and 2 patients are currently alive and clinically disease-free
more than 5 years from the start of the i.p. treatment program. We
conclude that a subset of patients with peritoneal mesothelioma,
principally those with small-volume residual disease following surgical
tumor debulking, can benefit from a cisplatin-based i.p. treatment
strategy with control of ascites and prolonged disease-free survival. J
Cancer Res Clin Oncol1992, vol. 118, pages 547-550 GERMANY Markman M
and Kelsen DBreast/Gynecology Oncology Service, Memorial
Sloan-Kettering Cancer Center, New York, New York 10021. * * * * * * *
* * * Year: 1991 Death certificate categorization of malignant pleural
and peritoneal mesothelioma in a cohort of asbestos insulation workers.
Abstract: Accuracy of diagnosis of malignant mesothelioma (pleural and
peritoneal) was studied in a cohort of asbestos insulation workers in
the United States and Canada. Initial clinical diagnosis, clinical
diagnosis at death and death certificate diagnosis were compared with
the diagnosis of malignant mesothelioma ascertained by full data review
at the Division of Environmental and Occupational Medicine, Mount Sinai
Medical Center, New York ('best evidence'). In both groups the death
certificate diagnosis was somewhat less frequently accurate than
clinical diagnosis at death. Knowledge of the patients' occupational
history by the attending physician and its relation to accuracy of
diagnosis of malignant mesothelioma is considered. Ribak J, Lilis R,
Suzuki Y, Penner L and Selikoff IJDivision of Environmental and
Occupational Medicine, Mount Sinai School of Medicine, City University
of New York.J Soc Occup Med1991 Autumn, vol. 41, pages 137-139 ENGLAND
* * * * * * * * * * Year: 1991 Asbestosis, laryngeal carcinoma, and
malignant peritoneal mesothelioma in an insulation worker. Abstract:
Asbestos associated diseases consist of both benign and malignant
conditions. A rare constellation of asbestosis, laryngeal carcinoma,
and malignant peritoneal mesothelioma occurring in a patient with long
term occupational exposure to airborne asbestos fibers is presented.
The observation illustrates the powerful disease-causing potential of
occupational exposure to asbestos. A brief discussion of multiple
primary neoplasms associated with exposure to asbestos is also
presented. Br J Ind Med1991 May, vol. 48, pages 338-341 Fischbein A and
Luo JCDepartment of Community Medicine, Mount Sinai School of Medicine,
University of New York, New York 10029. Mesothelioma | About Asbestosis
| Asbestos Related Lung CancerKnow Your Rights! | You Are Not Alone |
About Us | Contact UsArticles and Resources | Treatment Options |
What's New | Home Disclaimer

[Back to top]